pSivida Announces Phase I/II Clinical Study Evaluating Bioerodible, Sustained Release Latanoprost Device In Ocular Hypertension And Glaucoma

Drug delivery company pSivida Corp. (NASDAQ: PSDV) (ASX: PVA) today announced the commencement of a Phase I/II clinical trial studying a new bioerodible drug delivery implant for the treatment of glaucoma and ocular hypertension...

Full Story →